Cln5 Gene Ceroid Lipofuscinosis, Neuronal 5 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Attribute | Value | [@vines2001] |-----------|-------| | Gene Symbol | CLN5 | | Gene Name | Ceroid Lipofuscinosis, Neuronal 5 | | Official Full Name | CLN5, Lysosomal Trafficking Protein | | Chromosomal Location | 13q22.3 | | GRCh38 Coordinates | chr13:77,029,618-77,041,929 | | NCBI Gene ID | 1203 | | OMIM ID | 608096 | | Ensembl ID | ENSG00000157540 | | UniProt ID | Q9NWW5 | | Gene Family | CLN5 family |
</div>}
Overview
...
CLN5 Gene
Introduction
Cln5 Gene Ceroid Lipofuscinosis, Neuronal 5 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Attribute | Value | [@vines2001] |-----------|-------| | Gene Symbol | CLN5 | | Gene Name | Ceroid Lipofuscinosis, Neuronal 5 | | Official Full Name | CLN5, Lysosomal Trafficking Protein | | Chromosomal Location | 13q22.3 | | GRCh38 Coordinates | chr13:77,029,618-77,041,929 | | NCBI Gene ID | 1203 | | OMIM ID | 608096 | | Ensembl ID | ENSG00000157540 | | UniProt ID | Q9NWW5 | | Gene Family | CLN5 family |
</div>}
Overview
Mermaid diagram (expand to render)
The CLN5 gene encodes a lysosomal protein involved in the pathogenesis of neuronal ceroid lipofuscinosis (NCL). CLN5 is a soluble lysosomal protein that interacts with other NCL proteins to form a complex involved in lysosomal function and autophagy. Mutations in CLN5 cause variant forms of Batten disease, typically with late infantile or juvenile onset<sup>[1]</sup>.
Function
Protein Structure
CLN5 is a 407-amino acid soluble lysosomal glycoprotein (48 kDa). It contains a signal peptide for secretion and is targeted to lysosomes via mannose-6-phosphate-independent pathways<sup>[2]</sup>.
Deletion carriers: Classic late infantile phenotype
Missense/Missense: Variable, often later onset
Compound heterozygous: Intermediate presentation
Expression Patterns
Tissue Distribution: High in brain ([cortex](/brain-regions/cortex), cerebellum), retina
Brain Regions: Predominant in [neurons](/entities/neurons)
Cellular Localization: Lysosomal lumen
Developmental Expression: Increases during development
Transcript: 1.9 kb mRNA, 4 exons
Therapeutic Approaches
Current Treatments
Anticonvulsants: Seizure management
Supportive care: Multidisciplinary approach
Physical/occupational therapy: Maintain function
Experimental Therapies
Enzyme replacement: Recombinant CLN5 protein
Gene therapy: AAV-vector delivery in development
Stem cell therapy: Investigational approaches
Research Directions
Understanding CLN5 function in lysosomes
Developing gene therapy approaches
Characterizing protein interactions
Identifying biomarkers
Background
The study of Cln5 Gene Ceroid Lipofuscinosis, Neuronal 5 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Lebrun AH, et al, "CLN5 mutations cause autosomal recessive neuronal ceroid lipofuscinosis with severity correlated with mutation position." Hum Mutat (2012)
Schmiedt ML, et al, "CLN5 is phosphorylated by CK2." Mol Cell Biochem (2011)
Mole SE, et al, "The neuronal ceroid lipofuscinoses (Batten disease) gene family: a clinical perspective." Crit Rev Neurobiol (2005)
Vines DJ, et al, "Molecular genetics of the neuronal ceroid lipofuscinoses." Brain Res Bull (2001)
Pathway Diagram
The following diagram shows the key molecular relationships involving CLN5 Gene - Ceroid Lipofuscinosis, Neuronal 5 discovered through SciDEX knowledge graph analysis: